Evaluation of Cemiplimab in Combination With Platinum-Doublet Chemotherapy in First-Line (1L) Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) in Adult United States (US) Patients
Clinical trial NCT06269133 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT06269133
- Sponsor
- Regeneron Pharmaceuticals
- Status
- ACTIVE_NOT_RECRUITING
- Study type
- OBSERVATIONAL
- Start date
- 2024-02-21
- Primary completion
- 2027-03-31
- Enrollment
- 1000
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.